USPTO serial 76333309
INFUSE-X
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- PENDLETON, CAROLYN A
- Law office
- TMEG LAW OFFICE 103 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with INFUSE-X?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Glenn A. Gundersen
GLENN A GUNDERSEN DECHERT4000 BELL ATLANTIC TWR1717 ARCH STPHILADELPHIA, PA 19103-2793Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Laboratory, and manufacturing equipment for use in developing and manufacturing pharmaceuticals, nutraceuticals, chemicals, proteins, peptides, oligonucleotides, DNA, and vaccines using supercritical fluid technology | ACTIVE | — |
| 040 | Custom manufacturing of pharmaceuticals, nutraceuticals, chemicals, proteins, peptides, oligonucleotides, DNA, and vaccines using supercritical fluid technology to the order and/or specification of others | ACTIVE | — |
| 042 | Conducting feasibility studies for others on the use of supercritical fluids in the formulation of pharmaceuticals, nutraceuticals chemicals, proteins, peptides oligonucleotides, DNA, vaccines, other biotechnology-derived products, and other products; licensing of supercritical fluid technology; developing pharmaceuticals, nutraceuticals, chemicals, proteins, peptides, oligonucleotides, DNA, vaccines, other biotechnology-derived products, and other products for others using supercritical fluid technology | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 16, 2005 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Feb 16, 2005 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jul 20, 2004 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 27, 2003 | CFIT | CASE FILE IN TICRS | — |
| Oct 8, 2002 | CNSL | LETTER OF SUSPENSION MAILED | — |
| Oct 2, 2002 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 13, 2002 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 13, 2002 | PAPER RECEIVED | — | |
| Aug 12, 2002 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 11, 2002 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 29, 2002 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 25, 2002 | DOCK | ASSIGNED TO EXAMINER | — |